The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Popkova T.V.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Novikova D.S.

Nauchno-issledovatel'skiĭ institut revmatologii RAMN

Cardiovascular disease in rheumatic diseases

Authors:

Nasonov E.L., Popkova T.V., Novikova D.S.

More about the authors

Journal: Therapeutic Archive. 2016;88(5): 4‑12

DOI: 10.17116/terarkh20168854-12

Read: 6667 times

Download PDF (RU)
Contact the author
Table of contents

CARDIOVASCULAR DISEASE IN RHEUMATIC DISEASES
CARDIOVASCULAR DISEASE IN RHEUMATIC DISEASES

To cite this article:

Nasonov EL, Popkova TV, Novikova DS. Cardiovascular disease in rheumatic diseases. Therapeutic Archive. 2016;88(5):4‑12. (In Russ.)
https://doi.org/10.17116/terarkh20168854-12

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Role of doctor-patient communication in rheumatology. Russian Journal of Preventive Medi­cine. 2025;(4):156-161
Changes in diagnosis-related group payment model in the Russian Fede­ration in 2025. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):18-30
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Historical aspe­cts and prospects of psoriasis treatment. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):284-292
Mechanism of action of various therapies for viti­ligo. Pharmacologist’s and dermatovenerologist’s perspective. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):734-741
Abstract:

The representatives of immunoinflammatory diseases are rheumatic ones, such as primarily rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, and other systemic connective diseases, which are characterized by a high risk for untimely death. The high risk of untimely death in these diseases has been found to be associated with the severity of an immunoinflammatory process that gives rise to severe irreversible damage to vital organs and systems and with the development of a wide spectrum of comorbidities (infections, interstitial lung disease, malignant tumors, osteoporotic fractures, etc.). Among them, diseases of the cardiovascular system, which are most commonly caused by the early development and accelerated progression of atherosclerotic coronary lesions, hold a central position. The paper gives the data available in the recent literature on the impact of antirheumatic therapy (disease-modifying antirheumatic drugs and biological agents) on the cardiovascular system.

Keywords:

rheumatic diseases; risk factors for cardiovascular diseases; methotrexate; biological agents; cardiovascular risk

Authors:

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Popkova T.V.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Novikova D.S.

Nauchno-issledovatel'skiĭ institut revmatologii RAMN

Close metadata

References:

  1. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering diseases. J Autoimmun. 2009;33:197-207.  doi:10.1016/j.jaut.
  2. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Med. 2006;3:e297. doi:10.1371/journal.pmed.0030297.
  3. Wang L, Wang F-S, Gershwin ME. Human autoimmune disease: a comprehensive update. J Intern Med. 2015;278:369-395.  doi:10.1111/joim.12395.
  4. Doria A, Zen M, Bettio S et al. Autoinflammation and autoimmunity: Bridging the divide. Autoimm Rev. 2012;12:22-30.  doi:10.1016/j.autrev.2012.07.018.
  5. Pincus T, Gibson KA, Block JA. Premature mortality: a neglected outcome in rheumatic diseases? Arthritis Care Res. 2015;67:1043-1046. doi:10.1002/acr.22554.
  6. Cutolo M, Kitas GD, van Riel PLCM. Burden of disease in treated rheumatoid arthritis patients: going beyond the joints. Semin Arthritis Rheum. 2014;43:479-488.  doi:10.1016/j.semarthrit.2013.08.004.
  7. Nasonov E, Gordeev A, Galushko E. Rheumatic diseases and multimorbidity. Terapevticheskii arkhiv. 2015;5:4-9. (In Russ.)
  8. Crowson CS, Liao KP, Davis JM et al. Rheumatoid arthritis and cardiovascular disease Am Heart J. 2013;166:622-628.  doi:10.1016/j.ahj.2013.07.010.
  9. Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic disease. Nat Rev Rheumatol. 2015;11:693-704.  doi:10.1038/nrrheum.2015.112.
  10. Prasad M, Hermann J, Gabriel SE et al. Cardiorheumatology: cardiac involvement in systemic rheumatic diseases. Nat Rev Cardiol. 2015;12:168-176.  doi:10.1038/nrcardio.2014.206. 
  11. Smolen JS, Aletaha D, Bijsma JWJ et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force Ann Rheum Dis. 2010;69:631-637.  doi:10.1136/ard.2009.123919.
  12. Nasonov E, Mazurov V, Karateev D, Lukina G, Zhilyaev E, Amirdzhanova V, Muraviyov Y, Tchichasova N. Project: Recommedations on treatment of rheumatoid arthritis developed by all Russian public organization «Association of rheumatologists of Russia» — 2014 (PART 1). Nauchno-prakticheskaya revmatologiya. 2014;52(5):477-494. (In Russ.) doi:10.14412/1995-4484-2014-477-494.
  13. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.  doi:10.1136/annrheumdis-2013-204573.
  14. Avina-Zubieta J A, Thomas J, Sadatsafavi M, Lehman A J, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71:152401529. doi:10.1136/annrheumdis-2011-200726.
  15. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340:115.
  16. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
  17. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325.  doi:10.1038/nature10146.
  18. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124-2126.
  19. Nasonov E. Atherothrombosis problem in rheumatology. Vestnik RAMN. 2003;7:6-10. (In Russ.)
  20. Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11:390-400.  doi:10.1038/nrrheum.2015.40. 
  21. Barbarroja N, Perez-Sancherz C, Ouiz-Limon P et al. Anticyclic citrullinsted protein antibodies are implicated in the development of cardiovascular disease in rheumatoid arthritis. Arterioscler Thromb Vasc Biol. 2014;34:2706-2716. doi:10.1161/ATVBAHA.114.304475
  22. Kondratyeva L, Popkova Т, Nasonov Е. Metabolic syndrome in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2013;51(3):302-312. (In Russ.) doi:10.14412/1995-4484-2013-1506.
  23. Popkova T, Novikova D, Nasonov E. Atherosclerosis in rheumatic diseases. In the book: Genetically engineered biological agents in the treatment of rheumatoid arthritis. Ed. Nasonov E. Moscow: IMA-Press; 2013. (In Russ.)
  24. Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol. 2013;9:513-523.  doi:10.1038/nrrheum.2013.91.
  25. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-487.
  26. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67:1449-1455. doi:10.1002/art.39098.
  27. Nurmohamed MT. Editorial: Treat to Target in Rheumatoid Arthritis: Good for the Joints as Well as the Heart? Arthritis Rheum. 2015;67:1412-1415. doi:10.1002/art.39096.
  28. Nasonov E. Methotrexate: perspectives in rheumatology. M.: Filomatis; 2005. (In Russ.)
  29. Genetically engineered biological agents in the treatment of rheumatoid arthritis. Ed. Nasonov E.. Moscow: IMA-Press; 2013. (In Russ.)
  30. Siebert S, Tsoukas A, Robertson J, McInnes I. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol Rev. 2015;280-309.  doi:10.1124/pr.114.009639.
  31. Khan R, Spagnoli V, Tarddif J-C, L`Allier PL. Novel anti-inflammatory therapies for treatment of atherosclerosis. Atherosclerosis. 2015;240:497-509.  doi:10.1016/j.atherosclerosis.2015.04.783.
  32. Ridker PM, Lüscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;14(35):1782-1791. doi:10.1093/eurheartj/ehu203.
  33. Back M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015;12:199-211.  doi:10.1038/nrcardio.2015/5.
  34. Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL. Cardiovascular effects of methotrexate in rheumatoid arthritis. Curr Med Chem. 2015;22:1903-1910.
  35. Micha R, Imamura F, von Ballmoos MV et al. Systemic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362-1370. doi:10.1016/j.amjcard.2011.06.054.
  36. Roubille C, Richer V, Startino T et al. The effect of tumor necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Ann Rheunm Dis. 2015;74:480-489.  doi:10.1136/annrheumdis-2014-206624.
  37. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjustment association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum. 2013;65:334-342.  doi:10.1002/art.37723.
  38. Bulgarelli A, Martins Dias AA, Caramelli B, Maranhao RC. Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol. 2012;59:308-314.  doi:10.1097/FJC.0b013e318241c385.
  39. Nasonov E. Methotrexate in rheumatoid arthritis — 2015: new facts and ideas. Nauchno-prakticheskaya revmatologiya. 2015;53:64-76. (In Russ.)
  40. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012;71(7):1157-1162. doi:10.1136/annrheumdis-2011-200493.
  41. Erhayiem B, Pavitt S, Baxter P et al. Coronary artery disease evaluation in rheumatoid arthritis (CADERA): study protocol for a randiomized controlled trial. Trials. 2014;15:436.
  42. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res. 2011;63:522-529.  doi:10.1002/acr.20371.
  43. Daïen CI, Duny Y, Barnetche T, Daurès JP, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis. 2012;71:862-868.  doi:10.1136/annrheumdis-2011-201148.
  44. Mann DL, McMurray JJ, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
  45. Chung ES, Packer M, Lo KH et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
  46. Udachkina E.V., Novikova D.S., Popkova T.V., Nasonov E.L. Rheumatoid arthritis and atherosclerosis: Role of interleukin-6. Klinicheskaya farmakologiya i terapiya. 2012;21(1):86-92.
  47. Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379:1205-1213. doi:10.1016/S0140-6736(11)61931-4.
  48. Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214-1224. doi:10.1016/S0140-6736(11)61931-4.
  49. Popkova T, Novikova D, Panasyuk E, Avdeeva A, Udachkina E, Alexandrova E, Novikov A, Volkov A, Nasonov E. Tocilizumab impact on blood cholesterol transport and early manifestation of atherosclerosis in patients with rheumatoid arthritis. Terapevticheskii arkhiv. 2012;5:9-18. (In Russ.)
  50. Udachkina E, Novikova D, Popkova T, Nasonov E. Dynamics of blood lipid parameters in patients with rheumatoid arthritis in the combined therapy tocilizumab and methotrexate compared to methotrexate monotherapy at 24-week follow-up. Ratsional’naya farmakoterapiya v kardiologii. 2015;11(5):510-516. (In Russ.)
  51. Rao VU, Pavlov A, Klearman M, Musselman D, Giles JT, Bathon JM, Sattar N, Lee JS. An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy. Arthritis Rheum. 2015;67(2):372-380.  doi:10.1002/art.38920.
  52. Novikova DS, Popkova TV, Nasonov EL. The effect of anti-B-cell therapy on the development of atherosclerosis in patients with rheumatoid arthritis. Cur Pharm Des. 2012;18:1512-1518.
  53. Tsiantoulas D, Sage AP, Mallat Z, Binder JC. Targeting B Cells in Atherosclerosis Closing the Gap From Bench to Bedside. Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35:296-302.  doi:10.1161/ATVBAHA.114.303569.
  54. Novikova DS, Popkova TV, Lukina GV et al. The effects of rituximab on lipids, arterial stiffness, and carotid intima-media thickness in rheumatoid arthritis. J Korean Med Sci. 2016;31:202-207.  doi:10.3346/jkms.2016.31.2.202.
  55. Novikova D, Popkova T, Gerasimova E, Novikov A, Aleksandrova E, Nasonov E. Changes in heart rate, heart rate variability and QT interval in women with rheumatoid arthritis during rituximab treatment. Nauchno-prakticheskaya revmatologiya. 2014;52(3):270-276. (In Russ.) doi:10.14412/1995-4484-2014-270-276.
  56. Nasonov E, Eliseev M. The role of interleukin-1 in the development of human disease. Nauchno-prakticheskaya revmatologiya. 2016;54 (accepted for publication). (In Russ.)
  57. Dinarello CA. An expanding role for interleukin-1 blockade from gout to cancer. Molecular Med. 2014;20(Suppl 1):S43-S58.  doi:10.2119/molmed.2014.00232.
  58. Van Tassell BW, Noldo S, Mezzaroma E, Abbate A. Targeting Interleukin-1 in Heart Disease. Circulation. 2013;128:1910-1923  doi:10.1161/CIRCULATIONAHA.113.003199.
  59. Ridker P M, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605.  doi:10.1016/j.ahj.2011.06.012.
  60. The Interleukin 1 genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonists: a Mendelian randomization analysis. Lancet Diabetes Endocrinol. 2015;3:243-253.  doi:10.1016/S2213-8587(15)00034-0.
  61. Liu S-H, Xie L, Zhang J et al. Gout and risk of myocardial infarction: a systemic review and meta-analysis of cohort studies. PLOS ONE. 2015. doi:10.1371/journal.pone.0134088.
  62. Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colhicine in the treatment of gout. Clin Ther. 2014;36:1465-1479. doi:10.1016/j.clinthera.2014.07.017.
  63. Novikova D, Popkova T, Nasonov E, Novikova D, Popkova T, Nasonov E. Reduction of cardiovascular risk in rheumatoid arthritis: double benefit of statins. Nauchno-prakticheskaya revmatologiya. 2010;48(6):61-71. (In Russ.) doi:10.14412/1995-4484-2010-826.
  64. Xing B, Yin Y-F, Zhao L-D et al. Effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor on disease activity in patients with rheumatoid arthritis. Medicine. 2015;94:e572.
  65. Schoenfeld SR, Lu L, Rai SK et al. Statin use and mortality in rheumatoid arthritis: a general population-based study. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2015-207714.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.